Abstract
The identification of the causes of cancer at the cellular level has led to the discovery of the Epidermal Growth Factor Receptor (EGFR)/Ras/Mitogen-Activated Protein Kinase (MAPK) signaling pathway as a target for the development of anti-cancer strategies. A variety of therapeutic approaches to inhibit the EGFR/Ras/MAP module are currently being tested in clinical trials or have even been approved for the treatment of some tumors. However, more efficient ways to block the EGFR/Ras/MAPK pathway in tumor cells still have to be developed. The subcellular localisation of each member of this module is of pertinent importance to ensure signaling. Accumulating evidence suggests that targeting/scaffold proteins regulate the assembly, localization and activity of EGFR/Ras/MAPK signal transduction components. In particular proteins that stimulate the lysosomal downregulation of the EGFR and the targeting of Ras regulators/effectors to Ras could contribute to improve strategies to inhibit EGFR/Ras signaling in cancer. These proteins include the Cbl/CIN85/endophilin pathway, caveolin, galectins, annexins, Impedes Mitogenic Signal Propagation (IMP), 14-3-3 and Kinase Suppressor of Ras (KSR). Here we will review the current literature regarding the potential of targeting/scaffold proteins to affect the lysosomal targeting of EGFR and the subcellular localization of the Ras/MAPK signaling cascade.
Keywords: EGF receptor, Ras/Raf/MAPK pathway, cancer, scaffolds, adaptors
Current Signal Transduction Therapy
Title: Involvement of Targeting and Scaffolding Proteins in the Regulation of the EGFR/Ras/MAPK Pathway in Oncogenesis
Volume: 1 Issue: 2
Author(s): Thomas Grewal, Francesc Tebar, Albert Pol and Carlos Enrich
Affiliation:
Keywords: EGF receptor, Ras/Raf/MAPK pathway, cancer, scaffolds, adaptors
Abstract: The identification of the causes of cancer at the cellular level has led to the discovery of the Epidermal Growth Factor Receptor (EGFR)/Ras/Mitogen-Activated Protein Kinase (MAPK) signaling pathway as a target for the development of anti-cancer strategies. A variety of therapeutic approaches to inhibit the EGFR/Ras/MAP module are currently being tested in clinical trials or have even been approved for the treatment of some tumors. However, more efficient ways to block the EGFR/Ras/MAPK pathway in tumor cells still have to be developed. The subcellular localisation of each member of this module is of pertinent importance to ensure signaling. Accumulating evidence suggests that targeting/scaffold proteins regulate the assembly, localization and activity of EGFR/Ras/MAPK signal transduction components. In particular proteins that stimulate the lysosomal downregulation of the EGFR and the targeting of Ras regulators/effectors to Ras could contribute to improve strategies to inhibit EGFR/Ras signaling in cancer. These proteins include the Cbl/CIN85/endophilin pathway, caveolin, galectins, annexins, Impedes Mitogenic Signal Propagation (IMP), 14-3-3 and Kinase Suppressor of Ras (KSR). Here we will review the current literature regarding the potential of targeting/scaffold proteins to affect the lysosomal targeting of EGFR and the subcellular localization of the Ras/MAPK signaling cascade.
Export Options
About this article
Cite this article as:
Grewal Thomas, Tebar Francesc, Pol Albert and Enrich Carlos, Involvement of Targeting and Scaffolding Proteins in the Regulation of the EGFR/Ras/MAPK Pathway in Oncogenesis, Current Signal Transduction Therapy 2006; 1 (2) . https://dx.doi.org/10.2174/157436206777012066
DOI https://dx.doi.org/10.2174/157436206777012066 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis and Biological Evaluation of 3-Substituted-4-(4-methylthio phenyl)-1HPyrrole Derivatives as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Thyroid Hormones Crosstalk with Growth Factors: Old Facts and New Hypotheses
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) A Lesion based and Sub-regional Comparison of FDG PET/CT and MDP Bone Scintigraphy in Detection of Bone Metastasis in Breast Cancer
Current Medical Imaging Modulation of Toll-Like Receptor 4. Insights from X-Ray Crystallography and Molecular Modeling
Current Topics in Medicinal Chemistry Pregabalin in Neuropathic Pain: Evidences and Possible Mechanisms
Current Neuropharmacology 1,4-Benzothiazines-A Biologically Attractive Scaffold
Mini-Reviews in Medicinal Chemistry Recent Patents on the Baculovirus Systems
Recent Patents on Biotechnology Osteogenic Peptides in Bone Regeneration
Current Pharmaceutical Design Development and Application of Fourier-Transform Infrared Chemical Imaging of Tumour in Human Tissue
Current Medicinal Chemistry Recent Advances of Metal Binding Protein Lactoferrin as an Anti- Microbial Agent
Current Bioactive Compounds Clinical Applicability of Conditioning Techniques in Ischemia-Reperfusion Injury: A Review of the Literature
Current Cardiology Reviews Aneuploidy-Inducing Mutations in Mitotic Checkpoint Protein hMad1-Carboxi Terminal Domain Analyzed by SAR and Computational Mutagenesis
Current Proteomics Recent Progress in the Development of Natural ent-Kaurane Diterpenoids with Anti-tumor Activity
Mini-Reviews in Medicinal Chemistry The mTOR Signaling Network: Insights from Its Role During Embryonic Development
Current Medicinal Chemistry Chlorophylls and their Derivatives Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry The Role of Toll-Like Receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: A New Promising Therapeutic Approach?
CNS & Neurological Disorders - Drug Targets Human 90 kDa Heat Shock Protein Hsp90 as a Target for Cancer Therapeutics
Current Chemical Biology Cationic Liposomes as Non-viral Vector for RNA Delivery in Cancer Immunotherapy
Recent Patents on Drug Delivery & Formulation Searching for Novel Cancer Chemopreventive Plants and their Products:The Genus Zanthoxylum
Current Drug Targets Role of Unani Medicines in Cancer Control and Management
Current Drug Therapy